Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Calcitonin Gene Related Peptide (CGRP) - Overview
Calcitonin Gene Related Peptide (CGRP) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Calcitonin Gene Related Peptide (CGRP) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Calcitonin Gene Related Peptide (CGRP) - Companies Involved in Therapeutics Development
AfaSci Inc
Aptarion biotech AG
Eli Lilly and Co
H. Lundbeck AS
Living Cell Technologies Ltd
Nepsone ehf
Pharmnovo AB
Serometrix LLC
Teva Pharmaceutical Industries Ltd
Calcitonin Gene Related Peptide (CGRP) - Drug Profiles
AFAP-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eptinezumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fremanezumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
galcanezumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LP-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOXL-41 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CGRP for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CGRP for Psoriasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Calcitonin Gene Related Peptide (CGRP) - Dormant Products
Calcitonin Gene Related Peptide (CGRP) - Discontinued Products
Calcitonin Gene Related Peptide (CGRP) - Product Development Milestones
Featured News & Press Releases
Oct 24, 2019: Teva to present new alyses of fremanezumab and country-specific burden of migraine at 24th World Congress of Neurology
Oct 02, 2019: EMGALITY (galcanezumab) now available in Cada for preventive treatment of migraine
Sep 05, 2019: Alder BioPharmaceuticals to Showcase Eptinezumab Data from Migraine Prevention Portfolio at 19th Congress of the Intertiol Headache Society
Sep 05, 2019: Lilly’s migraine treatment Emgality lands in Korea
Sep 03, 2019: Teva to Present New Alyses of Fremanezumab Efficacy and Safety in Adult Patients with Difficult-to-Treat Migraine at 19th Congress of the Intertiol Headache Society
Aug 21, 2019: Fremanezumab data in The Lancet demonstrate clinically meaningful reduction in monthly migraine days versus Placebo for patients with difficult-to-treat migraine
Aug 06, 2019: Lilly reports positive data from CONQUER study of Emgality
Jul 15, 2019: Lilly’s Emgality shows favourable profile in Phase III studies
Jul 11, 2019: New England Jourl of Medicine publishes positive phase 3 data for Emgality (galcanezumab-gnlm) in episodic cluster headache
Jul 11, 2019: Alder BioPharmaceuticals presents new data on migraine-free months, migraine severity and quality of life, demonstrating eptinezumab’s clinical profile for migraine prevention
Jul 10, 2019: Teva to present new data on AJOVY (fremanezumab-vfrm) injection at the American Headache Society’s 61st Annual Scientific Meeting
Jul 09, 2019: Teva’s Fremanezumab improves migraine-related disorders, quality of life
Jul 08, 2019: Alder BioPharmaceuticals to showcase 14 new data presentations demonstrating Eptinezumab’s migraine prevention and quality of life impact at American Headache Society Meeting
Jul 04, 2019: Teva reports positive data from fremanezumab’s migraine trial
Jun 19, 2019: Alder BioPharmaceuticals to webcast upcoming breakfast symposium with key opinion leaders
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AfaSci Inc, H2 2019
Pipeline by Aptarion biotech AG, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by H. Lundbeck AS, H2 2019
Pipeline by Living Cell Technologies Ltd, H2 2019
Pipeline by Nepsone ehf, H2 2019
Pipeline by Pharmnovo AB, H2 2019
Pipeline by Serometrix LLC, H2 2019
Pipeline by Teva Pharmaceutical Industries Ltd, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019